Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases

This publication has 31 references indexed in Scilit:

• Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases
  European Journal of Surgical Oncology, 2008
• Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases
  BMC Cancer, 2008
• Bevacizumab, Capecitabine, and Oxaliplatin As Neoadjuvant Therapy for Patients With Potentially Curable Metastatic Colorectal Cancer
  Journal of Clinical Oncology, 2008
• Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
  The Lancet, 2008
• Antiangiogenic Therapy: A Universal Chemosensitization Strategy for Cancer?
  Science, 2006
• Interdisciplinary management of colorectal cancer liver metastases
  European Surgery, 2006
• Influence of Preoperative Chemotherapy on the Risk of Major Hepatectomy for Colorectal Liver Metastases
  Annals of Surgery, 2006
• Sinusoidal Obstruction Syndrome Is a Major Feature of Hepatic Lesions Associated with Oxaliplatin Neoadjuvant Chemotherapy for Liver Colorectal Metastases
  Journal of the American College of Surgeons, 2006
• Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
  New England Journal of Medicine, 2004
• Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases
  Annals of Oncology, 2003